Patent · US Active

CD33 specific chimeric antigen receptors

US11787848B2 · kind B2 · utility

0Cited by
10References
45Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 7, 2017
Grant dateOct 17, 2023
Priority date
Expiry dateMay 13, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2510/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.